Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/06—Antimalarials
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to an agent for the treatment of cerebral malaria, which contains iloprost as the active ingredient, and to a method for producing this agent.
• Salts with physiologically compatible bases and its ⁇ -cyclodextrin clathrate are advantageously suitable for the treatment of cerebral malaria.
• iloprost in contrast to PGI, a stable prostacyclin derivative, has been known from European patent application EP 11591 since 1980, no other prostacyclin derivative has been investigated in this indication. It is therefore reasonable to assume that the published case was a spontaneous cure. It has now surprisingly been found that iloprost is effective in cerebral malaria.
• Inorganic and organic bases are suitable for the salt formation of iloprost.
• examples include: alkali metal hydroxides, such as sodium and potassium hydroxide.
• Alkaline earth metal hydroxides such as calcium hydroxide, ammonia, amines, such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, tristhydroxymethylD-methylamine, etc.
• the ⁇ -cyclodextrin clathrate is formed in accordance with EP 259468.
• the treatment of cerebral malaria by iloprost is not described and is also not directly related to the other pharmacological properties described in EP 11591.
• the dose of iloprost is 1-1500 ⁇ g / kg / day when administered to the human patient.
• the unit dose for the pharmaceutical acceptable carrier is 0.01-100 mg.
• the dosing of IV administration as a continuous infusion in common aqueous solvents e.g. 0.9% NaCl solution, preferably in doses between 0.1 ng / kg / in and 0.1 ⁇ g / kg / min.
• the invention thus also relates to medicaments based on iloprost and customary auxiliaries and carriers.
• the active ingredient according to the invention is intended to be used in conjunction with the customary auxiliaries known and used in galenics, e.g. are used to manufacture cerebral malaria remedies.
• the invention also relates to a process for the preparation of the agent according to the invention, which is characterized in that the compound which acts against cerebral malaria and the auxiliaries and carriers known per se are galenically formulated in a manner known per se.
• CBA / CA mice develop i.p. at 80 - 90Z between the 7th and Uth day the clinical picture of cerebral malaria with neurological symptoms (slowdown, paralysis, ataxia, convulsions), at which they die within a few hours (1-5 hours).
• neurological symptoms lowdown, paralysis, ataxia, convulsions
• the surviving mice die after 3-4 weeks of severe anemia with a parasite of over 50Z.
• Grau et a. (Science, Vol. 237 (1987)) have been able to demonstrate the decisive role of TNF in the pathogenesis and prognosis of this disease by the following results:
• mice susceptible to cerebral malaria show significantly increased serum TNF levels.
• NMRI mice Local sterile inflammation is set in NMRI mice by intraperitoneal injection of 2 l of starch solution. After 3-5 days, the animals are sacrificed and the macrophages obtained.
• heat-stable soluble antigen which is obtained with P.b. ANKA parasitic urine erythrocytes are used (2).
• the TNF-sensitive cell line WEHI 164 (to be obtained commercially) is used as the TNF assay. The extent of the cell lysis of WEHI 164 is proportional to the amount of TNF present.
• the culture supernatants and sera are titrated in a dilution series in 96-well flat-bottom microtiter plates. A titration series with TMU TNF is used as standard.
• the number of surviving cells is determined using the colorimetric MTT test.
• the calculation is carried out by comparison with the standard titration series from TMU TNF using probit analysis.
• the test allows a determination of up to 0.5 U / ml TNF.
• a TNF ⁇ and TNFß can be differentiated by adding an anti TNF antiserum.
• mice 15 mice are infected by the intraperitoneal administration of 1x10 parasitized erythrocytes. Simultaneously with the infection, 1 ⁇ g of iloprost (100 ⁇ l s.c) was given to 6 mice. This treatment is continued every day until the 10th day.
• mice in the control group are treated as described above, but receive 100 ⁇ l NaCl instead of iloprost.
• the parasite is determined daily (blood smear, Giemsa staining). Both groups achieve 10-fold parasitemia on day 10 post infection. From the control group, 8 out of 9 mice with previous cerebral symptoms died between days 8 and 14. The mice of the iloprost group show no cerebral symptoms at this time. The last mouse in the control group and the mice in the iloprost group die between the 24th and 30th day after infection from the consequences of severe anemia.
• the serum TNF levels of the untreated and the iloprost-treated mice are examined.
• Iloprost significantly inhibits TNF levels in the serum even 4 days after the last injection.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Tropical Medicine & Parasitology (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Engineering & Computer Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6425074

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (9)

Family Cites Families (3)

• 1991
  • 1991-02-12 DE DE4104606A patent/DE4104606C1/de not_active Expired - Lifetime
• 1992
  • 1992-02-07 AT AT92904592T patent/ATE147628T1/de not_active IP Right Cessation
  • 1992-02-07 ES ES92904592T patent/ES2099247T3/es not_active Expired - Lifetime
  • 1992-02-07 DK DK92904592.0T patent/DK0571457T3/da active
  • 1992-02-07 DE DE59207900T patent/DE59207900D1/de not_active Expired - Lifetime
  • 1992-02-07 US US08/104,068 patent/US5466713A/en not_active Expired - Fee Related
  • 1992-02-07 AU AU12375/92A patent/AU663484B2/en not_active Ceased
  • 1992-02-07 WO PCT/DE1992/000091 patent/WO1992013537A1/de not_active Ceased
  • 1992-02-07 JP JP50411992A patent/JP3322311B2/ja not_active Expired - Fee Related
  • 1992-02-07 CA CA002103906A patent/CA2103906C/en not_active Expired - Fee Related
  • 1992-02-07 EP EP92904592A patent/EP0571457B1/de not_active Expired - Lifetime
• 1993
  • 1993-08-11 KR KR1019930702385A patent/KR100188164B1/ko not_active Expired - Fee Related
• 1997
  • 1997-03-18 GR GR970400545T patent/GR3022870T3/el unknown

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events